Economic Savings From a Rational Immunoglobulin Use Strategy in Patients With Primary Immunodeficiencies
Author(s)
Julio Cesar Orrego, Immunologist, Catalina Obando Gil, MD, Carolina Bedoya, MD, Alejandra Rendon, MSc, Juliana Madrigal Cadavid, MSc, Jorge Ivan Estrada, MSc. PhD Candidate.
Helpharma, Medellin, Colombia.
Helpharma, Medellin, Colombia.
OBJECTIVES: To describe the economic savings resulting from the implementation of a rational immunoglobulin use strategy in patients with primary immunodeficiencies.
METHODS: This observational, retrospective study was conducted in a cohort of patients diagnosed with primary immunodeficiency and treated with human immunoglobulin G within a specialized care program in 2024. A clinical and pharmacotherapeutic follow-up strategy was applied to optimize medication use, aiming to ensure safe, personalized, and cost-effective therapy. A univariate statistical analysis was performed using measures of central tendency, relative frequencies, and cumulative distributions. Data processing was conducted using the R Core Team statistical software, version 4.2 (2022).
RESULTS: A total of 55 patients were included, with a mean age of 29 years (SD = 22.6), of whom 51.2% were male. All patients were receiving treatment with normal human immunoglobulin G. Based on clinical and pharmacotherapeutic monitoring individualized interventions were implemented by the treating immunologist, including dose adjustments (70.7%), treatment discontinuation (17.0%), and extension of administration intervals (12.2%). These measures maintained therapeutic effectiveness and disease control, resulting in an estimated total cost saving of USD 86,645
CONCLUSIONS: The rational use strategy of immunoglobulin therapy in patients with primary immunodeficiencies proved to be clinically effective and economically efficient, contributing to the optimization of healthcare resource utilization.
METHODS: This observational, retrospective study was conducted in a cohort of patients diagnosed with primary immunodeficiency and treated with human immunoglobulin G within a specialized care program in 2024. A clinical and pharmacotherapeutic follow-up strategy was applied to optimize medication use, aiming to ensure safe, personalized, and cost-effective therapy. A univariate statistical analysis was performed using measures of central tendency, relative frequencies, and cumulative distributions. Data processing was conducted using the R Core Team statistical software, version 4.2 (2022).
RESULTS: A total of 55 patients were included, with a mean age of 29 years (SD = 22.6), of whom 51.2% were male. All patients were receiving treatment with normal human immunoglobulin G. Based on clinical and pharmacotherapeutic monitoring individualized interventions were implemented by the treating immunologist, including dose adjustments (70.7%), treatment discontinuation (17.0%), and extension of administration intervals (12.2%). These measures maintained therapeutic effectiveness and disease control, resulting in an estimated total cost saving of USD 86,645
CONCLUSIONS: The rational use strategy of immunoglobulin therapy in patients with primary immunodeficiencies proved to be clinically effective and economically efficient, contributing to the optimization of healthcare resource utilization.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
HSD41
Topic
Health Service Delivery & Process of Care, Real World Data & Information Systems
Disease
Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)